Complete title: APEC1621C, NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF TAZEMETOSTAT IN PATIENTS WITH TUMORS HARBORING ALTERATIONS IN EZH2 OR MEMBERS OF THE SWI/SNF COMPLEX
| Research Study Number | APEC1621C |
| Principal Investigator | Navin Pinto, MD |
| Phase | II |
Other eligibility criteria may apply.
| Research Study Number | APEC1621C |
| Contact | Navin Pinto, MD |
| Telephone | 206/987-2106 |
Keywords: Central Nervous System (CNS); Glioma; Hematologic Malignancies; Lymphoma; Lymphoproliferative Disorders; Medulloblastoma; Pediatric Cancers, Miscellaneous; Neuroblastoma; Lymphoma, Non-Hodgkin (NHL); Neuroectodermal Tumors, Primitive (PNET); Sarcoma; Solid Tumors; Wilms' Tumor; Neoplasms, Germ Cell and Embryonal; Immunoproliferative Disorders; Neuroectodermal Tumors; Ependymoma; Rhabdomyosarcoma; Sarcoma, Ewing; Neoplasms, Neuroepithelial; Osteosarcoma; Neoplasms, Connective and Soft Tissue; Immune System Diseases; Rhabdoid Tumor; Histiocytoma; Nervous System Diseases; Histiocytosis, Langerhans-Cell; Hepatoblastoma; Neuroectodermal Tumors, Primitive, Peripheral
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.